
Learn how to engage your Medical Provider Network, train supervisors, guide injured employees to care, and support a smoother return-to-work process.

As Medicare continues to evolve under the Inflation Reduction Act, prescription drug costs are becoming more predictable for beneficiaries, yet many still explore additional savings tools like GoodRx. Understanding how GoodRx interacts with 2026 Medicare Part D rules can help make smarter pharmacy decisions.
Beginning January 1, 2026, Medicare Part D includes several major updates:
These updates significantly change how beneficiaries experience their drug coverage and may impact when GoodRx is or isn’t a cost‑effective alternative.
GoodRx is a discount program, not insurance. It provides cash‑price coupons through pharmacy and PBM partnerships, often lowering retail prices for certain medications. But it does not coordinate with Medicare Part D:
Even with the new $2,100 cap, there are times when GoodRx may offer meaningful savings:
However, beneficiaries using GoodRx should be aware that savings achieved this way may delay reaching the new $2,100 cap, which could otherwise provide full coverage for medications later in the year.
GoodRx remains a useful tool, but with the 2026 Medicare Part D $2,100 out‑of‑pocket cap, beneficiaries should evaluate whether coupon savings today may impact their overall drug costs for the year. As always, comparing Part D plan prices, coupon prices, and formulary coverage at the point of sale is key to making the best financial decision.